Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock

Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Bellicum. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.